Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 687 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vector Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

NCT02661373
View directory record Official record
Conditions
Malaria
Interventions
SJ733, Cobicistat
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Oct 23, 2026, 1:50 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

NCT06899802
View directory record Official record
Conditions
Encephalitis
Interventions
MVA-BN-WEV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 50 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Sacramento, California • Lilburn, Georgia • Lenexa, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 23, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous Gene Therapy for Artemis-Deficient SCID

NCT03538899
View directory record Official record
Conditions
Severe Combined Immunodeficiency
Interventions
AProArt-CD34, CliniMACS® CD34 Reagent System cell sorter device, Busulfan
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2038
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 1:50 AM EDT
Active, not recruiting No phase listed Observational

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

NCT06162585
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy product-MCO-010
Biological
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 23, 2026, 1:50 AM EDT
Completed No phase listed Observational

Diagnosis and Characterization of Dengue Fever in Children

NCT00946218
View directory record Official record
Conditions
Dengue Fever
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 11 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Oct 23, 2026, 1:50 AM EDT
Terminated Phase 1Phase 2 Interventional

A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis

NCT04273269
View directory record Official record
Conditions
GM1 Gangliosidosis
Interventions
LYS-GM101
Genetic
Lead sponsor
LYSOGENE
Industry
Eligibility
Up to 3 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 23, 2026, 1:50 AM EDT
Recruiting Not applicable Interventional

Sana Device for Post-Treatment Lyme Disease Syndrome Chronic Pain

NCT06655844
View directory record Official record
Conditions
Post-treatment Lyme Disease Syndrome, Chronic Pain
Interventions
Sana Pain Reliever, Sham SPR
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL

NCT01713439
View directory record Official record
Conditions
Neuroblastoma
Interventions
Injection of allogeneic neuroblastoma cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 23, 2026, 1:50 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease

NCT04148222
View directory record Official record
Conditions
Lyme Disease, Lyme Disease, Chronic
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses

NCT02215707
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine
Biological
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1 Interventional

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy

NCT01787994
View directory record Official record
Conditions
HIV
Interventions
Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 23, 2026, 1:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07732400
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
VV-14303
Genetic
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chandler, Arizona • Lady Lake, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 1:50 AM EDT
Terminated Phase 3 Interventional Results available

Symptomatic Management of Lyme Arthritis

NCT04038346
View directory record Official record
Conditions
Lyme Arthritis, Lyme Disease, Arthritis
Interventions
Naproxen, Acetaminophen
Drug
Lead sponsor
Desiree Neville, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

NCT06026514
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
B/HPIV3/S-6P
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 23, 2026, 1:50 AM EDT
Withdrawn Phase 1 Interventional

Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

NCT00706615
View directory record Official record
Conditions
Breast Cancer
Interventions
Ad-sig-hMUC-1/ecdCD40L vaccine
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 23, 2026, 1:50 AM EDT
Terminated No phase listed Observational Results available

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

NCT03278873
View directory record Official record
Conditions
Achromatopsia
Interventions
Prior exposure to AAV-CNGA3 or AAV-CNGB3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Not applicable Interventional Results available

Vector Engineering Clinical

NCT04725500
View directory record Official record
Conditions
COPD
Interventions
Auto-Titrating EPAP
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
40 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Youngstown, Ohio • Clairton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT03897309
View directory record Official record
Conditions
Norovirus Infection
Interventions
VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

NCT00427167
View directory record Official record
Conditions
Malaria
Interventions
AMA1-C1/Alhydrogel + CPG 7909 (Saline), AMA1-C1/Alhydrogel + CPG 7909 (Phosphate), AMA1-C1/Alhydrogel + CPG 7909
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults

NCT04966871
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8) for CHMI, Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 23, 2026, 1:50 AM EDT
Not listed No phase listed Observational

The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey

NCT05312619
View directory record Official record
Conditions
COVID-19, Lyme Disease, COVID-19 Vaccine
Interventions
Cross sectional survey
Other
Lead sponsor
Dr. Daniel Cameron & Associates
Other
Eligibility
12 Years and older
Enrollment
2,000 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Mount Kisco, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

NCT04786444
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
Biological Vaccine VLA1553
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 45 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Coral Gables, Florida • Fort Myers, Florida • Ponte Vedra, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 1:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 1:50 AM EDT